Plain-English translation of NCT06739811 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing the Medtronic Implantable Insulin Pump System (MIIPS 2020), a small pump designed to be surgically implanted in your body to deliver insulin directly inside your abdomen. The trial is for adults with type 1 diabetes whose blood sugar cannot be controlled well with standard insulin pumps or injections, even when experiencing frequent dangerous highs and lows. If the treatment works well, you may be able to continue using the device after the study ends.
Many people with type 1 diabetes struggle to keep their blood sugar stable despite their best efforts with standard insulin therapy, leading to exhausting and dangerous blood sugar swings. This trial exists to test whether delivering insulin directly into the abdomen — rather than under the skin — can provide better, more stable blood sugar control.
You likely qualify if…
You likely don't qualify if…
The study lasts about 6 months. First, you will have a run-in period where the researchers collect baseline data while you continue your current insulin therapy. Then you will have surgery to implant the pump under your skin in your abdomen, and it will deliver insulin directly inside your body. Throughout the study, you will attend regular visits, wear a continuous glucose monitor, check your blood sugar as directed, and work with the study team to adjust your pump settings based on your glucose readings. If all goes well, you may be able to continue using the implanted device after the study ends.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
France